GHK-Cu Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained
HealthRX.com
GHK-Cu has no FDA-approved medicine yet
Key numbers
- 0.4%Strength of the copper tripeptide cream tested in the venous ulcer trial, which did not differ from placebo on ulcer sizeSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 86 evaluable patientsEvaluable patients in the venous stasis ulcer trial comparing a copper cream, placebo and silver sulfadiazineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 13 patientsPatients who completed the trial of GHK-Cu skin care after CO2 laser resurfacing around the mouthSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- P=.04Statistical significance of the patient questionnaire favoring GHK-Cu for overall skin quality after laser treatmentSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Registered clinical studies of GHK-Cu
ClinicalTrials.gov lists 4 registered studies that name GHK-Cu as an intervention as of 2026-11-11. Of these, 1 are recruiting, 1 are completed and 0 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 4 |
| Recruiting now | 1 |
| Not yet recruiting | 1 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 0 |
| Phase 2 (including phase 1/2) | 1 |
| Phase 1 | 1 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches GHK-Cu or GHK copper or copper tripeptide-1, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
From the public record
Published papers mentioning GHK-Cu
PubMed indexes 93 papers that mention GHK-Cu in the title or abstract, 55 of them published from 2016 to 2025. The count for 2025 is 9 and for 2024 is 8.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 93 | |
| Published 2016 to 2025 | 55 | |
| Published in 2025 | 9 | |
| Published in 2024 | 8 | |
| Busiest year since 2016 | 2023 | 13 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'GHK-Cu' or 'GHK copper' or 'copper tripeptide-1' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
From the public record
FDA product listings naming GHK-Cu
The FDA NDC Directory holds 10 listings naming GHK-Cu from 8 firms: 8 bulk ingredient listings and 2 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming GHK-Cu | 10 | |
| Bulk ingredient listings | 8 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 1 | |
| Finished product listings | 2 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 8 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains GHK-Cu or GHK copper or copper tripeptide-1
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
At a glance
- FDA-approved GHK-Cu medicines / None [1]
- Approved copper drug often confused with it / Copper histidinate (Zycubo), approved January 12, 2026 for Menkes disease — a different compound [4]
- Cosmetic copper peptide serums / Sold without FDA approval; a disease claim would make the product a drug [2]
- Compounded non-injectable GHK-Cu / Category 1, under evaluation for the bulks list, added back May 14, 2026 [1][5]
- Injectable GHK-Cu / In FDA's 'nominated but withdrawn' table, with an immunogenicity concern [3]
- Next regulatory step / FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote yet [1]
- Compounded drugs generally / Not FDA-approved; no FDA review of safety, effectiveness or quality before marketing [6]
- Human randomized trials found / 13 patients (after laser resurfacing) and 86 patients (venous ulcers, where a 0.4% copper tripeptide cream was no different from placebo) [11][7]
Is 'Medical-Grade' GHK-Cu an FDA Category?
No. No FDA-approved drug is known to contain GHK-Cu; FDA treats it as a nominated bulk drug substance for compounding, not an approved medicine [1]. A copper peptide product may be a cosmetic, a compounded drug, or an unapproved injectable that FDA lists as nominated but withdrawn, and what 'medical-grade' means depends on which of these it is [1][2][3].
The copper drug that does hold an approval is a different compound. Zycubo (copper histidinate) was approved on January 12, 2026 for Menkes disease in children; copper histidinate is not the GHK copper complex [4].
What 'Research-Only' Actually Means
A 'research use only' label by itself does not make a product a cosmetic or an FDA-approved drug. Under the FD&C Act, intended use is what separates a cosmetic from a drug: claims to treat or prevent disease, or to change the structure or function of the body, make a product a drug, and cosmetic ingredients other than color additives do not need FDA approval before sale. FDA looks at how a product is marketed, including its labeling, advertising and other claims [2].
Cosmetic Copper Peptide Creams and Serums
Skin-care serums and creams with copper peptide are sold as cosmetics, and whether a product is a cosmetic or a drug depends on its intended use and marketing claims [2]. Strength is set by the manufacturer and is not FDA-reviewed; the one drug-style human trial found used a 0.4% tripeptide copper complex cream [7].
A topical can cross into drug territory. FDA gives claims to restore hair growth, reduce cellulite or regenerate cells as examples that make a product a drug [2]. One sunscreen with GHK-Cu in its name lists UV filters, not GHK-Cu, as its active ingredients [8].
For information about a topical copper peptide product, see copper peptide cream.
Compounded GHK-Cu From a State-Licensed Pharmacy
Non-injectable GHK-Cu is on the list FDA maintains for state-licensed pharmacies and physicians. 'GHK-Cu (except for injectable routes of administration)' is in category 1 — the group FDA is evaluating for the compounding bulks list — and FDA says it generally does not intend to act against compounders of category 1 substances when the conditions in its guidance are met [1][5].
The listing moved twice in 2026. GHK-Cu was removed from category 1 on April 22, 2026 when the nominations were withdrawn; on May 5, 2026 a nominator clarified it had withdrawn only the injectable route, and FDA added non-injectable GHK-Cu back to the list, updated May 14, 2026 [1][5]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about whether GHK-Cu belongs on the bulks list before the end of February 2027; no vote has happened [1].
FDA's page says bulk substances used by state-licensed pharmacies and physicians in compounding must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [6].
Injectable GHK-Cu: A Different Status
FDA's page on bulk substances that may present significant safety risks, content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' in its 'nominated but withdrawn' table. FDA's stated concern is that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [3].
Injectable GHK-Cu is not in category 1, and not in any category on FDA's current list [1]. It also does not appear on FDA's list for outsourcing facilities, updated March 21, 2025 [9]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [2].
What the HHS October 2026 Peptide Policy Did Not Cover
HHS's October 2026 draft enforcement-discretion policy names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [10]. GHK-Cu is not one of them.
What the Human Studies Show
The human trials found were topical and small to moderate in size; none tested an injectable product.
A randomized trial published in 2006 tested post-treatment skin care with or without GHK-Cu after CO2 laser resurfacing of the skin around the mouth; 13 patients completed it. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, in wrinkles, or in overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [11].
In a prospective randomized evaluator-blinded trial in venous stasis ulcers, 86 evaluable patients were compared across a 0.4% tripeptide copper complex cream, an inert vehicle placebo, and silver sulfadiazine 1%. The copper cream was no different from placebo on ulcer size; silver sulfadiazine reduced it [7].
A 2026 systematic review screened 1,247 records covering 2005 to 2026 and kept 64 for qualitative synthesis. Its authors describe the human literature as thin and fragmented, note that most randomized trials are small and run on facial cosmetic creams, and state that microneedle delivery of GHK-Cu has yet to be evaluated in a single registered, adequately powered human randomized controlled trial [12].
A narrative review by the researchers who proposed the peptide's actions reports collagen and proteoglycan stimulation, metalloproteinase modulation, attraction of immune and endothelial cells to injury, and faster wound healing in dogs, rats, mice and pigs, plus cosmetic effects such as firmer skin and fewer fine lines. These come from laboratory, animal and company-type data rather than randomized trials, and they are proposed mechanisms, not proven human effects [13].
What Differs Between Products
For a topical, the difference is regulatory category: cosmetics are not approved before sale, and the claims decide whether the product is legally a drug [2]. For a compounded non-injectable preparation, the difference is the pharmacy's position under category 1 and the fact that FDA has not reviewed the finished preparation [1][5][6]. For an injectable, FDA has approved no GHK-Cu injection and has published a specific immunogenicity concern [3].
Athletes have one more consideration. GHK-Cu is not named on WADA's 2026 Prohibited List or its 2027 List, but WADA's S0 class covers substances with no approval from any governmental health authority, and the 2027 notes say peptides not specifically named may still be prohibited — so the absence of the name is not a clearance [14][15].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Questions worth asking
Frequently asked questions
Is medical-grade GHK-Cu FDA-approved?
Are copper peptide serums FDA-approved?
Can a state-licensed pharmacy compound GHK-Cu?
What is FDA's position on injectable GHK-Cu?
What do human trials of GHK-Cu show?
Does the October 2026 HHS peptide policy cover GHK-Cu?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What is better, topical or injectable GHK-Cu?
No form is ranked as better. Injectable GHK-Cu is in FDA's 'nominated but withdrawn' table, with a stated immunogenicity concern about aggregation and peptide-related impurities. The human trials found were all topical, and none tested an injectable product.
Is GHK-Cu clinically proven?
Not established. The human trials are small, and a 2026 systematic review calls the human literature thin and fragmented. A 2006 trial of 13 patients found no significant difference in objective measures after laser resurfacing, and an 86-patient venous ulcer trial found the copper cream no different from placebo on ulcer size. The collagen and wound-healing effects come from lab and animal data and are proposed mechanisms, not proven human effects.
What is the best GHK-Cu peptide to buy?
No product is named as best. Products differ by regulatory pathway: cosmetic topicals are not FDA-approved before sale, non-injectable compounded GHK-Cu is in category 1, and FDA has approved no GHK-Cu injection. Strength in cosmetic products is set by the manufacturer and is not FDA-reviewed.
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7.
- U.S. National Library of Medicine, DailyMed. MELAO GHK-Cu PEPTIDE SUNSCREEN (butyl methoxydibenzoylmethane,ethylhexyl salicylate,homosalate,octocrylene) prescribing information. MELAO GHK-Cu PEPTIDE SUNSCREEN (butyl methoxydibenzoylmethane,ethylhexyl salicylate,homosalate,octocrylene) label
- U.S. Food and Drug Administration.
- Official web page.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9.
- Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.
- World Anti-Doping Agency.
- World Anti-Doping Agency.